TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23558770

Group type: EXPERIMENTAL
Intervention: ICM group (AH at the site near the inner cell mass)
Number of subjects: 160

Group type: COMPARATOR
Intervention: TE group (AH at the site opposite to the ICM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ICM group
Number of subjects: 160

Group type: COMPARATOR
Intervention: TE group
Number of subjects: 160
Study: 22013155

Group type: EXPERIMENTAL
Intervention: Dynamic casting method for foot orthoses
Number of subjects: 12

Group type: COMPARATOR
Intervention: Static casting method for foot orthoses
Number of subjects: 12
Study: 19255890

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (1,260 mg eicosapentaenoic acid and 540 mg docosahexaenoic acid/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (placebo) capsules
Number of subjects: 0
Study: 16499636

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Untreated (UT)
Number of subjects: 25
Study: 12921816

Group type: EXPERIMENTAL
Intervention: Angiotensin‐receptor blockade (ARB) with valsartan
Number of subjects: 14703

Group type: COMPARATOR
Intervention: Angiotensin‐converting enzyme inhibition (ACEI) with captopril
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Both ARB and ACEI
Number of subjects: 14703
Study: 10534827

Group type: EXPERIMENTAL
Intervention: Telemedical prenatal monitoring
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (standard prenatal care)
Number of subjects: 263
Study: 8546481

Group type: EXPERIMENTAL
Intervention: Three-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Four-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Number of subjects: 50
Study: 2063675

Group type: EXPERIMENTAL
Intervention: Phototherapy (PT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-phototherapy (non-PT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (serum bilirubin < 12 mg/dl)
Number of subjects: 29
Study: 6356865

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 3914859

Group type: EXPERIMENTAL
Intervention: Ceftazidime (500 mg intravenously every 12 h)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Moxalactam (500 mg intravenously every 12 h; 2 g for Pseudomonas aeruginosa)
Number of subjects: 67
Study: 29024341

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet (LGI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High glycemic index diet (HGI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tertile 1 (BW change)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tertile 2 (waist circumference)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tertile 1 (fat mass)
Number of subjects: 48
Study: 26394246

Group type: EXPERIMENTAL
Intervention: HOOP (uncommon exercise stimulus)
Number of subjects: 120

Group type: COMPARATOR
Intervention: WALK (common exercise stimulus)
Number of subjects: 120
Study: 24944129

Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 22636824

Group type: EXPERIMENTAL
Intervention: Increase fruit/vegetable intake and decrease sedentary leisure
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Decrease fat and increase physical activity
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Decrease fat and decrease sedentary leisure
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Increase fruit/vegetable intake and increase physical activity
Number of subjects: 204
Study: 20423561

Group type: EXPERIMENTAL
Intervention: Anserine (specific doses, intraperitoneal administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anserine (0.1 mg, intraduodenal injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of anserine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thioperamide (control)
Number of subjects: 0
Study: 18286418

Group type: EXPERIMENTAL
Intervention: Lenient recall instructions (recall everything, not worry about mistakes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict recall instructions (recall only if sure of accuracy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criterion manipulation in memory recognition with a confederate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varied level of secrecy in responses
Number of subjects: 0
Study: 16412924

Group type: EXPERIMENTAL
Intervention: Nuclear cataract patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posterior subcapsular cataract patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ARMD patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nuclear cataract and ARMD patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posterior subcapsular cataract and ARMD patients
Number of subjects: 100
Study: 12846845

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (200 ml per day, concentration 2.5 mg F- per litre) consumed from Monday to Friday in kindergarten and two packs of fluoridated milk (250 ml) for home consumption on weekends.
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (children without access to fluoridated milk).
Number of subjects: 534
Study: 10512601

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for up to 8 weeks with ERT
Number of subjects: 172

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily for up to 8 weeks without ERT
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Fluoxetine responders treated up to 26 weeks
Number of subjects: 172
Study: 8744879

Group type: EXPERIMENTAL
Intervention: Physicians provided with Hamilton Depression rating scale (HAM-D) scores and patient-specific treatment recommendations
Number of subjects: 222

Group type: COMPARATOR
Intervention: Physicians not provided HAM-D scores
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Provision of treatment algorithms
Number of subjects: 222
Study: 1755876

Group type: COMPARATOR
Intervention: Regular smokers
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Smokers given counselling
Number of subjects: 491
Study: 6314097

Group type: COMPARATOR
Intervention: Conjugated equine oestrogens
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Piperazine oestrone sulphate
Number of subjects: 2
Study: 30465175

Group type: EXPERIMENTAL
Intervention: Acotiamide 300 mg/day for 2 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 71
Study: 30015604

Group type: EXPERIMENTAL
Intervention: Usual food choices identified using the Apriori algorithm
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Breakfast food choices
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Lunch food choices
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Dinner food choices
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Other meal choices
Number of subjects: 433
Study: 26853954

Group type: EXPERIMENTAL
Intervention: Active group (≥1 min/week exercise)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Inactive group (0 min/week exercise)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Modest exercise (1 to 89 min/week)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Television screen time (>4 vs <2 h/day)
Number of subjects: 902
Study: 25150954

Group type: EXPERIMENTAL
Intervention: Oral letrozole (2.5mg/day) and norethindrone acetate (2.5mg/day) for three months prior to surgery (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment before surgery (group B)
Number of subjects: 80
Study: 21947680

Group type: EXPERIMENTAL
Intervention: Arm A (21-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1-14; paclitaxel 60 mg/m2, days 1, 8, and 15)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Arm B (28-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1-5, 8-12, and 15-19; paclitaxel 80 mg/m2, days 1, 8, and 15)
Number of subjects: 130
Study: 19153970

Group type: EXPERIMENTAL
Intervention: Doubly robust generalized estimating equations (DR GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted generalized estimating equations (WGEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imputation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INITIO randomized clinical trial of HIV therapy
Number of subjects: 0
Study: 17555692

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mineral trioxide aggregates (MTA)
Number of subjects: 34
Study: 15789590

Group type: EXPERIMENTAL
Intervention: Dose-Volume Histogram (DVH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dose-Surface Histogram (DSH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Digitized computation
Number of subjects: 60
Study: 12218390

Group type: EXPERIMENTAL
Intervention: Niacin, 3000 mg/day for > or = 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not applicable (self-perceived IAF expansion group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not applicable (IAF area comparison)
Number of subjects: 70
Study: 10485774

Group type: EXPERIMENTAL
Intervention: IVRA with clonidine (1 microg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (intravenous saline)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous clonidine (1 microg/kg)
Number of subjects: 45
Study: 8930781

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2000 micrograms
Number of subjects: 12
Study: 1992574

Group type: EXPERIMENTAL
Intervention: Combined treatment (total androgen blockade with nilutamide)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Simple castration
Number of subjects: 208
Study: 6606393

Group type: EXPERIMENTAL
Intervention: Moxalactam, 250 mg every 12 h
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gentamicin, 1 mg/kg every 8 h
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 49
Study: 31842773

Group type: EXPERIMENTAL
Intervention: Xpert arm
Number of subjects: 6041

Group type: COMPARATOR
Intervention: Smear arm
Number of subjects: 6041
Study: 30204821

Group type: COMPARATOR
Intervention: Kinesio tape (KT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Proprioceptive-neuromuscular (PN) training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (modern dance technique classes)
Number of subjects: 33
Study: 26860641

Group type: EXPERIMENTAL
Intervention: Patent lower extremity bypass (LEB) grafts
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Critical stenosis
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Revision of critical stenosis
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Preoperative gangrene
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Black race vs white race
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Baseline creatinine clearance <25 mL/min vs >65 mL/min
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Prior history of coronary artery bypass grafting
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Lower baseline activity quality of life score
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Postoperative gangrenous changes
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Surgical wound necrosis
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Deep wound infection vs superficial wound infection
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Wound healing abnormally
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Recurrent CLI symptoms
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Severe adverse event vs mild adverse event
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Fewer percutaneous revisions
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Discharge on low-molecular-weight heparin
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Decreasing days to critical stenosis/occlusion/revision/amputation
Number of subjects: 1404
Study: 24916552

Group type: EXPERIMENTAL
Intervention: Ice cream
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fat/protein component in ice cream
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sugar equivalent component in ice cream
Number of subjects: 11

Group type: COMPARATOR
Intervention: Avocado (kilojoule-equivalent meal)
Number of subjects: 11
Study: 22684984

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg M-W-F for 18-35.9 kg; 500 mg M-W-F for ≥36 kg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (initially) then Azithromycin
Number of subjects: 146
Study: 20433751

Group type: EXPERIMENTAL
Intervention: Phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 20
Study: 18608063

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (30 minutes of aerobic training followed by resistance training, twice weekly for six weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study: 15947903

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 628

Group type: COMPARATOR
Intervention: PDE5 inhibitors
Number of subjects: 628
Study: 11961396

Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 400 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 10205197

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus corticosteroids
Number of subjects: 70

Group type: COMPARATOR
Intervention: Azathioprine plus corticosteroids
Number of subjects: 70
Study: 7629406

Group type: EXPERIMENTAL
Intervention: naloxone (0.4 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ambulatory blood pressure and heart rates
Number of subjects: 28
Study: 2393295

Group type: EXPERIMENTAL
Intervention: Amifloxacin 200 mg q12h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin 400 mg q12h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin 600 mg q12h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin 400 mg q8h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin 600 mg q8h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin 800 mg q8h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin (all doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amifloxacin (doses above 1200 mg/day)
Number of subjects: 6
Study: 871444

Group type: EXPERIMENTAL
Intervention: Freon 11, Freon 12, Freon 114, and mixtures of these propellants
Number of subjects: 10
Study: 30551146

Group type: EXPERIMENTAL
Intervention: Hatha yoga (n = 25)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wellness control (reading educational materials about healthy lifestyle; n = 30)
Number of subjects: 55
Study: 31038996

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation
Number of subjects: 360

Group type: COMPARATOR
Intervention: No positive pressure ventilation
Number of subjects: 360
Study: 28472015

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted TAP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided TAP block
Number of subjects: 60
Study: 25231116

Group type: EXPERIMENTAL
Intervention: Accelerometer-augmented PLGS algorithm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular basal insulin rate (Control)
Number of subjects: 18
Study: 23731705

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 78
Study: 20850953

Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19496957

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (70 mg/kg magnesium sulphate infusions in 4 hours for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaCl 0.9% solutions (control for blinding purposes)
Number of subjects: 10
Study: 16957566

Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus metformin
Number of subjects: 389

Group type: COMPARATOR
Intervention: Glyburide plus metformin
Number of subjects: 389
Study: 15352664

Group type: EXPERIMENTAL
Intervention: Intraoperative EMG monitoring (n = 67)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group without EMG monitoring (n = 45)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Monitored group (n = 67)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 11259226

Group type: EXPERIMENTAL
Intervention: Standard services plus extra training for foster carers on communication and attachment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard services alone
Number of subjects: 182
Study: 9277243

Group type: EXPERIMENTAL
Intervention: Current Important Message from Medicare
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternatives for informing beneficiaries of their rights
Number of subjects: 0
Study: 7838460

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclophenac sodium
Number of subjects: 60
Study: 3277398

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment of mild-to-moderate hypertension
Number of subjects: 34000
Study: 31719052

Group type: EXPERIMENTAL
Intervention: Sustained-release oral morphine
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 31124516

Group type: EXPERIMENTAL
Intervention: Retrobulbar block with 0.5% ropivacaine plus dexmedetomidine 1 μg/kg (group RD, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retrobulbar block with 0.5% ropivacaine (group RB, n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia only (group F, n = 20)
Number of subjects: 60
Study: 28277409

Group type: EXPERIMENTAL
Intervention: Iodine povacrylex-alcohol (IPA)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Chlorhexidine-alcohol
Number of subjects: 788
Study: 27146668

Group type: EXPERIMENTAL
Intervention: PRGF application at the donor site
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no PRGF application)
Number of subjects: 43
Study: 23398551

Group type: EXPERIMENTAL
Intervention: Web-based intervention plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 22108483

Group type: EXPERIMENTAL
Intervention: Acustop
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (follow-up only)
Number of subjects: 42
Study: 19250113

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance imaging (CMR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: (99m)Tc‐2‐methoxy isobutyl isonitrile single photon emission computed tomography (SPECT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 24
Study: 16709204

Group type: EXPERIMENTAL
Intervention: 400 micrograms of oral misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 micrograms of oral misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 micrograms of vaginal misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14750007

Group type: EXPERIMENTAL
Intervention: Force-velocity test (F-V)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wingate test
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral temperature measurement
Number of subjects: 19
Study: 11728919

Group type: EXPERIMENTAL
Intervention: 10 mg of oral alendronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (with 500 mg of calcium in the form of daily calcium carbonate)
Number of subjects: 100
Study: 9155502

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 11
Study: 8190388

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 3069206

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily for the first 3 months)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 29494417

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 (100,000 IU), n = 2041
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo, n = 2014
Number of subjects: 5108

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 (100,000 IU), n = 559 (21.9%)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo, n = 593 (23.3%)
Number of subjects: 5108

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 (100,000 IU)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 (100,000 IU) in vitamin D deficient participants (<50 nmol/L, 24.9%)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo in vitamin D deficient participants
Number of subjects: 5108
Study: 26473755

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 126
Study: 24942404

Group type: EXPERIMENTAL
Intervention: LY2603618 (130-275 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LY2603618 (≥240 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Number of subjects: 14